Global Cancer Nanomedicine Market, By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier - Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) – Industry Trends and Forecast to 2030.
Cancer Nanomedicine Market Analysis and Size
According to the International Agency for Research on Cancer, there will be 10.3 million cancer deaths and 19.3 million new cancer cases worldwide in 2020. Furthermore, 16.4 million people are expected to die from cancer-related causes by 2040, with 29.5 million new patients diagnosed each year. One of the primary reasons for the increasing prominence of nanomedicine is the rise in the prevalence of chronic diseases such as cancer and cardiovascular disease. Furthermore, the market for cancer nanomedicine is expanding due to increased number of patients with high blood pressure, obesity, and other cardiovascular diseases, among other factors.
Data Bridge Market Research analyses that the cancer nanomedicine market which was USD 180 billion in 2022, is expected to reach USD 445.67 billion by 2030, at a CAGR of 12% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cancer Nanomedicine Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier - Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Alnylam Pharmaceuticals, Inc. (U.S.), Amgen Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), AstraZeneca (U.K.), Cadila Pharmaceuticals (India), CELGENE CORPORATION (U.S.), Celsion Corporation (U.S.), Genzyme (U.S.), Merck & Co., Inc. (U.S.), Nippon Kayaku Co.,Ltd. (Japan), Nanobiotix (France), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), General Electric (U.S.), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Nanomedicine is a branch of nanotechnology that uses nanoparticles to diagnose, treat, monitor, and control biological systems. By manipulating materials at the nanoscale, it improves medicine delivery. As a result, nanomedicine has helped treat a wide range of diseases. Nanomedicine is still in its infancy, with numerous products in the works. Nanobiotix has identified 230 nanomedicine products that are either patented or in the early stages of development. 49 of the 230 products are on the market, while the remaining 122 are in clinical trials, either in Phase II or Phase III trials.
Global Cancer Nanomedicine Market Dynamics
Drivers
- New product launches
Nanotechnology-based liposome products may be considered one of the most advanced segments of oncology medications. For instance, Ortho Pharmaceuticals' Doxil was one of the first cancer nanomedicines approved by the US FDA in 1995 for treating AIDS-related Kaposi's sarcoma. DaunoXome by Galen Ltd is a liposomal formulation used to treat HIV-related Kaposi sarcoma, and clinical trials for this medicine in leukaemia are also being conducted. More products are in various stages of clinical trials and will be introduced into the global market in the coming years.
- Usage of nanoparticle-based imaging agents
Because of their small size, nanoparticles are easily absorbed by cells and researchers used this property to aid in disease diagnosis. Oncologists can gain a better understanding of tumour shape and size, as well as precise location, for better treatment. A few nanoparticle-based imaging agents on the market are used for Magnetic Resonance (MR) imaging. SPIO nanoparticles used in imaging include Endorem by Guerbet, Resovist by Bayer, and Feridex by Berlex Laboratories. Aside from oncology, they are also used to diagnose cardiovascular and neurological diseases, propelling the market's growth.
Opportunities
- Increasing Demand for Nanomedicines
The growing demand for nanomedicines can be attributed to the rapidly expanding applications of nanomaterials such as nanocapsules and nanotubes in drug delivery systems. The rise in cancer and cardiovascular disease incidences has boosted demand for nanomedicines, resulting in increased public and private investment in nanomedicine research and advancements in biodegradable nanoparticles. The cost-effectiveness and fewer side effects of these therapies are also major drivers of the cancer nanomedicine industry's growth.
Restraints/Challenges
- Side effects associated with the consumption of nanoparticles
The low rate of adoption, the increasing side effects associated with the consumption of nanoparticles, and the stringent regulatory framework for drug approvals are acting as market restraints for the growth of the cancer nanomedicine market during the forecast period.
This cancer nanomedicine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer nanomedicine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Cancer Nanomedicine Market
According to reports, COVID-19 positively impacts the cancer nanomedicine market. This was due to increased demand for nanomedicines to treat medical conditions similar to cancer. Furthermore, nanomedicine applications opened up new avenues for the development of innovative solutions for the prevention, detection, and treatment of viral diseases such as the COVID-19 virus, boosting the growth of the cancer nanomedicine industry. The active involvement of well-established pharmaceutical companies in the development of novel Nano science-based therapeutics is expected to influence market growth. Furthermore, advances in nanotechnology and its expanding applications in preventive interventions, early disease diagnosis, chronic and acute disorder prevention, and acute and chronic disorder prophylaxis of acute as well as chronic disorders are the factors expected to drive the cancer nanomedicine industry growth.
Recent developments
- In 2021, The national nanotechnology effort received more than USD 1.7 billion in funding from the US government, highlighting the importance of nanotechnology. Furthermore, Forbes ranks nanotechnology as the sixth most important growth technology to watch over the next ten years.
Global Cancer Nanomedicine Market Scope
The cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Inorganic Nanoparticles
- Synthesis of gold nanoparticle
- Organic Nanoparticles
- Polymeric nanoparticle
- lipid organic nanoparticles
Agent Type
- Diagnostic Agents
- Cancer biomarkers
- Diagnostic device
- Biosensors
- Microarrays
- Nanoprobes
- Quantum dots
- Therapeutic Agents
- Photodynamic therapy
- Photo thermal therapy
- Drug Delivery Agents
Mechanism
- Targeting Tumor Cells
- Passive targeting
- Active targeting
- Nanocarrier - Drug Complex
- Liposomes
- Dendrimers
- Micelles
- Inorganic nanocarriers
- Drug Release Systems
Cancer Type
- Breast Cancer
- Pancreatic Cancer
- Brain Cancer
- Lung Cancer
- Others
Imaging Technique
- Positron Emission Tomography
- Single Photon Emitted Tomography
- Magnetic Resonance Imaging (MRI)
Phase
- Research
- Preclinical
- Phase-I
- Phase-I/II
- Phase-II
- Phase-III
Cancer Nanomedicine Market Regional Analysis/Insights
The cancer nanomedicine market is analyzed and market size insights and trends are provided by country, type, agent type, mechanism, cancer type, imaging technique, and phase as referenced above.
The countries covered in the cancer nanomedicine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cancer nanomedicine market due to the growing number of research and development activities along with the prevalence of various start-ups organizations.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the surging levels of investment for research and development activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cancer Nanomedicine Market Share Analysis
The cancer nanomedicine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer nanomedicine market.
Some of the major players operating in the cancer nanomedicine market are:
- Alnylam Pharmaceuticals, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Arrowhead Pharmaceuticals, Inc. (U.S.)
- AstraZeneca (U.K.)
- Cadila Pharmaceuticals (India)
- CELGENE CORPORATION (U.S.)
- Celsion Corporation (U.S.)
- Genzyme (U.S.)
- Merck & Co., Inc. (U.S.)
- Nippon Kayaku Co.Ltd. (Japan)
- Nanobiotix (France)
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- General Electric (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Gilead Sciences, Inc. (U.S.)
- Novartis AG (Switzerland)
Research Methodology: Global Cancer Nanomedicine Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-